Michael Happes, MD
Cardiology · Smithtown, NYNPI 1801030762
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $18,372 of the $29,703 with a category attached, or 61.9%. 25 manufacturers reported payments, led by Abbott at 58.6% of the total. Reporting peaked in 2024 at $12,079 and has fallen 59.5% since, to $4,888 in 2025. Among cardiology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 346 payments — averaging $85.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$17K
- Medtronic$4K
- Inari Medical, Inc.$2K
- Abiomed$2K
- Stryker$675
- Novartis$595
- plus $3K from 19 others
What the payments were for
- Consulting fees$3,00010%
- Speaking & faculty fees$7,50025%
- Travel & lodging$8303%
- Food & beverage$18,37262%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 142 | $17,409 |
| Medtronic(2 entities) | 34 | $3,880 |
| Inari Medical, Inc. | 33 | $2,445 |
| Abiomed | 16 | $1,781 |
| Stryker | 9 | $675 |
| Novartis | 36 | $595 |
| Edwards Lifesciences | 3 | $438 |
| Boston Scientific | 10 | $375 |
| Penumbra, Inc. | 5 | $344 |
| Philips North America LLC | 4 | $234 |
| Atricure, Inc. | 3 | $222 |
| Johnson & Johnson | 8 | $209 |
| E.r. Squibb & Sons, L.L.C. | 11 | $197 |
| Veryan Medical Incorporated | 1 | $154 |
| Cardiovascular Systems Inc. | 1 | $144 |
| AstraZeneca | 10 | $143 |
| Pfizer | 5 | $121 |
| Amgen | 4 | $92 |
| Shockwave Medical, Inc | 3 | $69 |
| Boehringer Ingelheim | 2 | $51 |
| Sanofi-aventis U.S. LLC | 2 | $40 |
| Kestra Medical Technology Services, Inc. | 1 | $31 |
| Heartflow, Inc. | 1 | $24 |
| Novo Nordisk | 1 | $18 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ultreon$4,329
- DRAGONFLY OPSTAR$4,000
- FLOWTRIEVER CATHETER, S$2,802
- XIENCE SIERRA$2,500
- Impella$1,413
- Mitra Clip system$1,361
- CT THROMBECTOMY SYSTEM KIT$1,127
- COREVALVE EVOLUT R$1,009
- Resolute$721
- SYMPLICITY G3$692
- FlowTriever$656
- CoreValve Evolut$630
- OPTIS$551
- MitraClip$392
- ClotTriever$381
- AMPLATZER Occluders$280
- Edwards SAPIEN 3 Transcatheter Heart Valve$262
- Xience Sierra Coronary Stent System$225
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$176
- Micra$170
How this compares
$29,703 in reported general payments places this provider in the 95th percentile of 112 cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 27 | $41,411 |
| BrilintaTicagrelor | 13 | $16,024 |
| EntrestoSacubitril/Valsartan | 13 | $14,562 |
| XareltoRivaroxaban | 19 | $14,093 |
| Metoprolol Succinate | 189 | $2,645 |
| Ranolazine ErRanolazine | 11 | $2,545 |
| Atorvastatin Calcium | 204 | $2,076 |
| Ezetimibe | 28 | $992 |
| Rosuvastatin Calcium | 61 | $877 |
| Losartan Potassium | 69 | $578 |
| Valsartan | 16 | $501 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 12 | $475 |
| Amlodipine Besylate | 85 | $407 |
| Lisinopril | 81 | $405 |
| ClopidogrelClopidogrel Bisulfate | 50 | $376 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $121 | $41,41127 claims |
| AstraZenecaBrilinta | $143 | $16,02413 claims |
| NovartisEntresto | $595 | $14,56213 claims |
| Johnson & JohnsonXarelto | $209 | $14,09319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 112 cardiology providers in New York.
Other cardiology in Smithtown
- David D'agateSmithtown$69K
- Saikrishna PatibandlaSmithtown$3K
- Rakesh PatelSmithtown$1K
- Eileen BishopSmithtown$1K
- Felix OviasuGarden City$150K
- Michael SiegalNew York$43K
- Michael AvaricioOzone Park$41K
- Bimalkumar BrahmbhattAmityville$31K
- Meyer AbittanRoslyn$28K
- Perminder GrewalStony Point$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.